Three distinct D-amino acid substitutions confer potent antiangiogenic activity on an inactive peptide derived from a thrombospondin-1 type 1 repeat.

Mal II, a 19-residue peptide derived from the second type 1 properdin-like repeat of the antiangiogenic protein thrombospondin-1 (TSP-1), was inactive in angiogenesis assays. Yet the substitution of any one of three L-amino acids by their D-enantiomers conferred on this peptide a potent antiangiogenic activity approaching that of the intact 450-kDa TSP-1. Substituted peptides inhibited the migration of capillary endothelial cells with an ED50 of 8.5 nM for the D-Ile-15 substitution, 10 nM for the D-Ser-4 substitution, and 0.75 nM for the D-Ser-5 substitution. A peptide with D-Ile at position 15 could be shortened to its last seven amino acids with little loss in activity. Like whole TSP-1, the Mal II D-Ile derivative inhibited a broad range of angiogenic inducers, was selective for endothelial cells, and required CD36 receptor binding for activity. A variety of end modifications further improved peptide potency. An ethylamide-capped heptapeptide was also active systemically in that when injected i.p. it rendered mice unable to mount a corneal angiogenic response, suggesting the potential usefulness of such peptides as antiangiogenic therapeutics.

[1]  H. Krutzsch,et al.  Antiproliferative and antitumor activities of D-reverse peptides derived from the second type-1 repeat of thrombospondin-1. , 2009, The journal of peptide research : official journal of the American Peptide Society.

[2]  Thomas Boehm,et al.  Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance , 1997, Nature.

[3]  David W. Dawson,et al.  CD36 Mediates the In Vitro Inhibitory Effects of Thrombospondin-1 on Endothelial Cells , 1997, The Journal of cell biology.

[4]  V. Dixit,et al.  Thrombospondin-1 suppresses tumorigenesis and angiogenesis in serum- and anchorage-independent NIH 3T3 cells. , 1997, Laboratory investigation; a journal of technical methods and pathology.

[5]  M. Stack,et al.  Lumen formation and other angiogenic activities of cultured capillary endothelial cells are inhibited by thrombospondin-1. , 1997, Microvascular research.

[6]  H. Krutzsch,et al.  Thrombospondin 1 and type I repeat peptides of thrombospondin 1 specifically induce apoptosis of endothelial cells. , 1997, Cancer research.

[7]  J M Pluda,et al.  Tumor-associated angiogenesis: mechanisms, clinical implications, and therapeutic strategies. , 1997, Seminars in oncology.

[8]  K. Dameron,et al.  Sequential development of an angiogenic phenotype by human fibroblasts progressing to tumorigenicity , 1997, Oncogene.

[9]  M. Stack,et al.  Human prostate carcinoma cells express enzymatic activity that converts human plasminogen to the angiogenesis inhibitor, angiostatin. , 1996, Cancer research.

[10]  E. Abel.  Clinical applications of research on angiogenesis , 1996 .

[11]  O. Volpert,et al.  Captopril inhibits angiogenesis and slows the growth of experimental tumors in rats. , 1996, The Journal of clinical investigation.

[12]  J. Folkman,et al.  A model of angiogenesis in the mouse cornea. , 1996, Investigative ophthalmology & visual science.

[13]  Yasufumi Sato,et al.  [Regulators of angiogenesis]. , 1996, Nihon yakurigaku zasshi. Folia pharmacologica Japonica.

[14]  N. Bouck,et al.  Inhibition of squamous cell carcinoma angiogenesis by direct interaction of retinoic acid with endothelial cells. , 1996, Laboratory investigation; a journal of technical methods and pathology.

[15]  O. Volpert,et al.  Inhibition of angiogenesis by thrombospondin-2. , 1995, Biochemical and biophysical research communications.

[16]  P. Bornstein.  Diversity of function is inherent in matricellular proteins: an appraisal of thrombospondin 1 , 1995, The Journal of cell biology.

[17]  P. Steeg,et al.  Transfection of thrombospondin 1 complementary DNA into a human breast carcinoma cell line reduces primary tumor growth, metastatic potential, and angiogenesis. , 1994, Cancer research.

[18]  Mark D. Johnson,et al.  Inhibition of angiogenesis by tissue inhibitor of metalloproteinase , 1994, Journal of cellular physiology.

[19]  H. Krutzsch,et al.  Modulation of endothelial cell proliferation, adhesion, and motility by recombinant heparin‐binding domain and synthetic peptides from the type I repeats of thrombospondin , 1993, Journal of cellular biochemistry.

[20]  R. J. Howard,et al.  Identification of SVTCG in thrombospondin as the conformation-dependent, high affinity binding site for its receptor, CD36. , 1993, The Journal of biological chemistry.

[21]  J. Lahav.  The functions of thrombospondin and its involvement in physiology and pathophysiology. , 1993, Biochimica et biophysica acta.

[22]  O. Volpert,et al.  Peptides derived from two separate domains of the matrix protein thrombospondin-1 have anti-angiogenic activity , 1993, The Journal of cell biology.

[23]  R. Silverstein,et al.  Sense and antisense cDNA transfection of CD36 (glycoprotein IV) in melanoma cells. Role of CD36 as a thrombospondin receptor. , 1992, The Journal of biological chemistry.

[24]  R. Nachman,et al.  Thrombospondin sequence motif (CSVTCG) is responsible for CD36 binding. , 1992, Biochemical and biophysical research communications.

[25]  S. Perkins,et al.  Neutron and X-ray scattering studies on the human complement protein properdin provide an analysis of the thrombospondin repeat. , 1991, Biochemistry.

[26]  M. L. Le Beau,et al.  A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[27]  C. Legrand,et al.  Developmentally regulated expression of a 78 kDa erythroblast membrane glycoprotein immunologically related to the platelet thrombospondin receptor. , 1989, The Biochemical journal.

[28]  D. Rifkin,et al.  Membrane and matrix localization of proteinases: a common theme in tumor cell invasion and angiogenesis. , 1988, Biochimica et biophysica acta.

[29]  R. Silverstein,et al.  Sense and Antisense cDNA Transfection of CD 36 ( Glycoprotein IV ) in Melanoma Cells , 2001 .

[30]  L. DiPietro.  Thrombospondin as a regulator of angiogenesis. , 1997, EXS.

[31]  N. Bouck,et al.  How tumors become angiogenic. , 1996, Advances in cancer research.

[32]  L. Daviet,et al.  Identification of an immunodominant functional domain on human CD36 antigen using human-mouse chimaeric proteins and homologue-replacement mutagenesis. , 1995, The Biochemical journal.

[33]  J. Fauchère,et al.  Evaluation of the stability of peptides and pseudopeptides as a tool in peptide drug design , 1992 .

[34]  N. Bouck,et al.  Assay and purification of naturally occurring inhibitor of angiogenesis. , 1991, Methods in enzymology.

[35]  J. Folkman,et al.  Angiogenic factors. , 1987, Science.

[36]  J. Morley.  Modulation of the action of regulatory peptides by structural modification , 1980 .